Open AccessClinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
Author(s) -
E. V. Biryukova,
Бирюкова Елена Валерьевна
Publication year - 2014
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm2014181-84
Subject(s) - vildagliptin , medicine , incretin , diabetes mellitus , type 2 diabetes mellitus , pharmacology , dipeptidyl peptidase 4 , type 2 diabetes , drug class , drug , endocrinology
The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4 inhibitors deepens every year, but to date only a few studies addressed direct comparison between individual agents within this pharmacological class. Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists.